Chemo-Pharma [CPL] vs Ashok Leyland [ASHOKLEY] Detailed Comparison
Chemo-Pharma
BSE
Loading...
Ashok Leyland
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Chemo-Pharma wins in 9 metrics, Ashok Leyland wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Chemo-Pharma | Ashok Leyland | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 13.21 | 23.10 | Chemo-Pharma |
| Price-to-Book Ratio | 2.96 | 5.86 | Chemo-Pharma |
| Debt-to-Equity Ratio | 44.70 | 315.50 | Chemo-Pharma |
| PEG Ratio | N/A | 15.74 | N/A |
| EV/EBITDA | 15.63 | 11.62 | Ashok Leyland |
| Profit Margin (TTM) | 10.92% | 6.40% | Chemo-Pharma |
| Operating Margin (TTM) | 10.65% | 19.26% | Ashok Leyland |
| EBITDA Margin (TTM) | 10.65% | 19.26% | Ashok Leyland |
| Return on Equity | 25.59% | 24.46% | Chemo-Pharma |
| Return on Assets (TTM) | 6.80% | 7.34% | Ashok Leyland |
| Free Cash Flow (TTM) | $41.66M | $-15.20B | Chemo-Pharma |
| Dividend Yield | N/A | 2.67% | N/A |
| 1-Year Return | 38.64% | -49.87% | Chemo-Pharma |
| Price-to-Sales Ratio (TTM) | 1.65 | 1.51 | Ashok Leyland |
| Enterprise Value | $5.03B | $1,133.64B | Ashok Leyland |
| EV/Revenue Ratio | 1.75 | 2.34 | Chemo-Pharma |
| Gross Profit Margin (TTM) | 31.19% | 38.46% | Ashok Leyland |
| Revenue per Share (TTM) | $52 | $83 | Ashok Leyland |
| Earnings per Share (Diluted) | $6.02 | $5.28 | Chemo-Pharma |
| Beta (Stock Volatility) | 0.35 | 0.34 | Ashok Leyland |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Chemo-Pharma vs Ashok Leyland Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Chemo-Pharma | -2.35% | 1.69% | 4.48% | -15.16% | -28.20% | -35.30% |
| Ashok Leyland | -2.28% | -0.25% | -50.15% | -45.81% | -38.19% | -45.27% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Chemo-Pharma | 38.64% | 393.51% | 115.30% | 982.62% | 1,384.38% | 1,384.38% |
| Ashok Leyland | -49.87% | -17.11% | 153.85% | 46.24% | 248.18% | 738.42% |
Performance & Financial Health Analysis: Chemo-Pharma vs Ashok Leyland
| Metric | CPL | ASHOKLEY |
|---|---|---|
| Market Information | ||
| Market Cap | ₹4.75B | ₹732.66B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 34,895 | 9,397,306 |
| 90 Day Avg. Volume | 36,751 | 9,298,443 |
| Last Close | ₹75.25 | ₹121.95 |
| 52 Week Range | ₹52.25 - ₹128.00 | ₹95.93 - ₹132.32 |
| % from 52W High | -41.21% | -7.84% |
| All-Time High | ₹128.00 (Jan 06, 2025) | ₹264.65 (Aug 26, 2024) |
| % from All-Time High | -41.21% | -53.92% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | 0.09% |
| Quarterly Earnings Growth | -0.04% | 0.32% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.06% |
| Operating Margin (TTM) | 0.11% | 0.19% |
| Return on Equity (TTM) | 0.26% | 0.24% |
| Debt to Equity (MRQ) | 44.70 | 315.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹26.86 | ₹20.83 |
| Cash per Share (MRQ) | ₹1.07 | ₹20.20 |
| Operating Cash Flow (TTM) | ₹89.49M | ₹1.28B |
| Levered Free Cash Flow (TTM) | ₹-72,916,248 | ₹30.87B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 2.67% |
| Last 12-Month Dividend | ₹0.00 | ₹6.25 |
Valuation & Enterprise Metrics Analysis: Chemo-Pharma vs Ashok Leyland
| Metric | CPL | ASHOKLEY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 13.21 | 23.10 |
| Forward P/E | N/A | 15.74 |
| PEG Ratio | N/A | 15.74 |
| Price to Sales (TTM) | 1.65 | 1.51 |
| Price to Book (MRQ) | 2.96 | 5.86 |
| Market Capitalization | ||
| Market Capitalization | ₹4.75B | ₹732.66B |
| Enterprise Value | ₹5.03B | ₹1.13T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.75 | 2.34 |
| Enterprise to EBITDA | 15.63 | 11.62 |
| Risk & Other Metrics | ||
| Beta | 0.35 | 0.34 |
| Book Value per Share (MRQ) | ₹26.86 | ₹20.83 |
Financial Statements Comparison: Chemo-Pharma vs Ashok Leyland
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CPL | ASHOKLEY |
|---|---|---|
| Revenue/Sales | ₹784.51M | ₹146.37B |
| Cost of Goods Sold | ₹539.82M | ₹90.07B |
| Gross Profit | ₹244.69M | ₹56.30B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹83.57M | ₹28.30B |
| EBITDA | ₹98.07M | ₹33.11B |
| Pre-Tax Income | ₹68.08M | ₹16.21B |
| Income Tax | ₹16.93M | ₹3.74B |
| Net Income (Profit) | ₹51.16M | ₹12.46B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CPL | ASHOKLEY |
|---|---|---|
| Cash & Equivalents | ₹12.05M | ₹65.45B |
| Total Current Assets | ₹2.51B | ₹342.40B |
| Total Current Liabilities | ₹1.17B | ₹265.51B |
| Long-Term Debt | ₹109.50M | ₹365.68B |
| Total Shareholders Equity | ₹1.49B | ₹158.45B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹144.04M | ₹62.89B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CPL | ASHOKLEY |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CPL | ASHOKLEY |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 34,895 | 9,397,306 |
| Average Daily Volume (90 Day) | 36,751 | 9,298,443 |
| Shares Outstanding | 57.55M | 2.94B |
| Float Shares | 15.95M | 3.33B |
| % Held by Insiders | 0.70% | 0.40% |
| % Held by Institutions | 0.00% | 0.28% |
Dividend Analysis & Yield Comparison: Chemo-Pharma vs Ashok Leyland
| Metric | CPL | ASHOKLEY |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹6.25 |
| Last 12-Month Dividend Yield | N/A | 2.67% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹5.80 |
| 3-Year Avg Dividend Yield | N/A | 1.54% |
| 3-Year Total Dividends | ₹0.00 | ₹17.40 |
| Ex-Dividend Date | N/A | May 22, 2025 |